Reporter brief
Natural senolytics with or without NLRP3 inhibitor reduced knee pain in osteoarthritis RCT
What happened
This randomized, double-blind, placebo-controlled trial enrolled 60 patients with symptomatic knee osteoarthritis and effusion-synovitis at a single Egyptian center. Participants received either quercetin plus fisetin alone (n=20), quercetin plus fisetin plus glycyrrhizin (n=20), or placebo (n=20) in intermittent dosing cycles over 15 weeks. Primary outcomes were change in knee pain (VAS) and effusion-synovitis volume on MRI; secondary outcomes included WOMAC scores, cartilage changes on T2 relaxation imaging, medication use, and quality of life measures.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
60 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis
- Design
- Rct
- Sample
- 60
- Journal
- Assiut University
- Published
- Jul 25, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.